Blocking ASCT2 with the inhibitor V9302 reduced cancer cell growth, triggered apoptosis, and suppressed the AKT/mTOR signaling pathway in both in vitro and in vivo models, without causing serious side effects. This evidence concerns the gene SLC1A5 and cancer.